Entegris Inc vs Revvity Inc — how do they compare? Entegris Inc trades at $165 (market cap $24.78B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays the higher dividend (0.25%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Revvity Inc for 12 Days on average.
| ENTG | RVTY | |
|---|---|---|
Market Cap | $24.78B | $16.98B |
Volume | 2,648,320 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $184.00 | $157.36 |
52-Week Low | $68.80 | $82.26 |
Typical Hold Time | 41 Days | 12 Days |
Enterprise Value | $27.99B | $19.30B |
Dividend Yield | 0.25% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $164.22, down 1.26% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected soon. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Analysts maintain a strong buy consensus with a $182.43 price target, indicating potential upside.
The outlook for ENTG is positive, driven by AI-related semiconductor demand and operational improvements. Key risks include high valuation multiples and exposure to semiconductor cycle volatility. Institutional accumulation and recent patent defenses support confidence, but investors should monitor execution against earnings expectations and industry capital spending trends.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →